Targeted therapy in gynecologic oncology: Biology, strategy, and assessment

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 155-156

  Sood, Anil K ^a   Coleman, Robert L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GEFITINIB; INTERLEUKIN 2; ISOTRETINOIN; PACLITAXEL; SUNITINIB;

CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; EDITORIAL; FOLLOW UP; GYNECOLOGIC CANCER; HAZARD; HUMAN; MOLECULAR IMAGING; OVARY CANCER; PRIORITY JOURNAL; SURGICAL TECHNIQUE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERUS CANCER;

DRUG DELIVERY SYSTEMS; FEMALE; GENITAL NEOPLASMS, FEMALE; GYNECOLOGY; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY;

EID: 73949112908     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.009     Document Type: Editorial

References (18)

1. Barnholtz-Sloan J.S., Schwartz A.G., Qureshi F., et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am. J. Obstet. Gynecol. 189 (2003) 1120-1127
2. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358 (2001) 781-786
3. Smith J.R., Boyle D.C., Corless D.J., et al. Abdominal radical trachelectomy: a new surgical technique for the conservative management of cervical carcinoma. Br. J. Obstet. Gynaecol. 104 (1997) 1196-1200
4. Covens A., Shaw P., Murphy J., et al. Is radical trachelectomy a safe alternative to radical hysterectomy for patients with stage IA-B carcinoma of the cervix?. Cancer 86 (1999) 2273-2279
5. Shepherd J.H., Mould T., and Oram D.H. Radical trachelectomy in early stage carcinoma of the cervix: outcome as judged by recurrence and fertility rates. BJOG 108 (2001) 882-885
6. Schlaerth J.B., Spirtos N.M., and Schlaerth A.C. Radical trachelectomy and pelvic lymphadenectomy with uterine preservation in the treatment of cervical cancer. Am. J. Obstet. Gynecol. 188 (2003) 29-34
7. Ramirez P.T., Schmeler K.M., Malpica A., et al. Safety and feasibility of robotic radical trachelectomy in patients with early-stage cervical cancer. Gynecol. Oncol. (2009)
8. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
9. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
10. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
11. Katsumata N., Yasuda M., Takahashi F., et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374 (2009) 1331-1338
12. Bookman M.A., Brady M.F., McGuire W.P., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27 (2009) 1419-1425
13. Monk B.J., Sill M.W., McMeekin D.S., et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a gynecologic oncology group (GOG) study. J. Clin. Oncol. (2008) 26
14. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25 (2007) 5180-5186
15. Burger R.A., Sill M.W., Monk B.J., et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 5165-5171
16. Aghajanian C., Sill M.W., Darcy K.M., et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) Study. J. Clin. Oncol. (2009) 27
17. Monk B.J., Sill M.W., Burger R.A., et al. Phase II trial of bevacizumab in the treatment of recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 108 (2008) S31
18. Holmes M.V., Shah T., Vickery C., et al. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 4 (2009) e7960